Top

Cancer Cell International

Published in:

Open Access 01-12-2023 | Retraction Note

Retraction Note: Silencing of TRIM11 suppresses the tumorigenicity of chordoma cells through improving the activity of PHLPP1/AKT

Authors: Bin Wang, Gang Wang, Qingfeng Wang, Ziqiang Zhu, Yunqing Wang, Kangwu Chen, Huilin Yang

Published in: Cancer Cell International | Issue 1/2023

Excerpt

Retraction Note: Cancer Cell Int (2019) 19:284 https://doi.org/10.1186/s12935-019-1007-7 …

Miao Y, Lu M, Yan Q, Li S, Feng Y. Inhibition of proliferation, migration, and invasion by knockdown of pyruvate kinase-M2 (PKM2) in ovarian cancer SKOV3 and OVCAR3 cells. Oncol Res. 2016;24(6):463–75. https://doi.org/10.3727/096504016X14685034103671.CrossRefPubMedPubMedCentral

Liang T, Ye X, Liu Y, Qiu X, Li Z, Tian B, Yan D. FAM46B inhibits cell proliferation and cell cycle progression in prostate cancer through ubiquitination of β-catenin. Exp Mol Med. 2018;50(12):1–12. https://doi.org/10.1038/s12276-018-0184-0.CrossRefPubMed

Zhang S, Wang Y, Chen S, Li J. Silencing of cytoskeleton-associated protein 2 represses cell proliferation and induces cell cycle arrest and cell apoptosis in osteosarcoma cells. Biomed Pharmacother. 2018;106:1396–403. https://doi.org/10.1016/j.biopha.2018.07.104.CrossRefPubMed

Shi J, Wang Q, Li H, Huang Q. Silencing of USP22 suppresses high glucose-induced apoptosis, ROS production and inflammation in podocytes Mol. BioSyst. 2016;12:1445–56. https://doi.org/10.1039/C5MB00722D.CrossRef

Title: Retraction Note: Silencing of TRIM11 suppresses the tumorigenicity of chordoma cells through improving the activity of PHLPP1/AKT
Authors: Bin Wang
Gang Wang
Qingfeng Wang
Ziqiang Zhu
Yunqing Wang
Kangwu Chen
Huilin Yang
Publication date: 01-12-2023
Publisher: BioMed Central
Published in: Cancer Cell International / Issue 1/2023
Electronic ISSN: 1475-2867
DOI: https://doi.org/10.1186/s12935-023-03017-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2023

Correction to: LncRNA WDFY3-AS2 promotes cisplatin resistance and the cancer stem cell in ovarian cancer by regulating hsa-miR-139-5p/SDC4 axis

Microbiome modulation in inflammatory diseases: Progress to microbiome genetic engineering

Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired

Disclosing a metabolic signature of cisplatin resistance in MDA-MB-231 triple-negative breast cancer cells by NMR metabolomics

Decoding the prognostic significance of integrator complex subunit 9 (INTS9) in glioma: links to TP53 mutations, E2F signaling, and inflammatory microenvironments

Epigallocatechin-3-gallate and cancer: focus on the role of microRNAs

Keynote webinar | Spotlight on antibody–drug conjugates in cancer